Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming. Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies. Clinical Data: Over 40 patients treated with … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, CREATE Medicines Bridges Science Strategy and Investment with Expanded RNA Platform for In Vivo Multi-Immune Therapies in Europe and Beyond, CREATE Medicines Integrates Scientific Progress and Investor Backing to Lead Multi-Lineage RNA Immunotherapy’s Next Chapter in Europe, CREATE Medicines Rebrand Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies, CREATE Medicines Reinforces Its Market and Research Focus Through RNA-Driven Multi-Lineage Immune Programming Amid Rising European Investment in mRNA Therapeutics, CREATE Medicines Strengthens Its Scientific and Strategic Position with Multi-Lineage RNA Platform and Investor Support Across a Growing European Biotech Market, CREATE Medicines’ New Identity Combines RNA-Based Scientific Leadership and Investor Momentum with Expanding Opportunities in European Immunotherapy Markets, CREATE Medicines’ Transition Marks New Phase in RNA Immunotherapy Development and Strategic Growth in Europe’s Expanding Biotech Landscape, Daniel Getts, Daniel Getts Ph.D., fibrosis, Following Its Rebrand, From Myeloid Therapeutics to CREATE Medicines: A Rebrand Uniting RNA Innovation Investor Confidence and Expanding European Immunotherapy Ambitions, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, himeric antigen receptor, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, Rebranded CREATE Medicines Aligns Scientific Innovation and Investor Backing to Advance RNA-Based In Vivo CAR Therapies in Global and European Markets, Rebranded CREATE Medicines Positions Itself at the Forefront of RNA Immunotherapy as Europe’s Biotech Ecosystem Accelerates Innovation, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
CREATE Medicines (“CREATE”) broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, providing clear differentiation among competitors and significant value potential for all stakeholders CREATE Medicines will … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, Daniel Getts, Daniel Getts Ph.D., fibrosis, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?